Abstract:This study investigates the potential of five compounds as novel anticancer agents. We examined their efficacy, mechanisms of action, and impact on various cancer cell lines, through a comprehensive set of experiments. Notably, compound 3e demonstrated superior activity compared to the positive control cisplatin, with a GI50 value of 6.3±0.7 μM against the breast cancer cell line (MCF‐7). Compound 3b also displayed remarkable growth inhibition, yielding GI50 values of 8.7±0.2 μM (MCF‐7) and 8.9±0.5 μM against the colon cancer cell line (HCT‐116). Cell count experiments further confirmed the potent inhibitory effects of compounds 3e, 3b, and 3c on MCF‐7 and HCT‐116 cell growth. Compound 3e demonstrated a reduction of 55–60 % at GI50 and complete inhibition (100 %) at 2x GI50. Compound 3b exhibited 50–55 % reduction (GI50) and 90–95 % inhibition (2x GI50) in HCT‐116 cells. Compound 3c displayed 75–80 % inhibition (2x GI50) and 35–40 % inhibition (GI50) in HCT‐116 cells. In‐depth mechanistic investigations unveiled valuable insights into the mode of action of compound 3e. The cell‐cycle assay demonstrated G2/M phase arrest, DNA damage, and caspase‐mediated apoptosis in both MCF‐7 and HCT‐116 cells. Caspase activation indicated a significant increase in apoptosis following exposure to compound 3e. Furthermore, compound 3e induced reactive oxygen species (ROS) production, influencing HCT‐116 and MCF‐7 cells differently. Elevated ROS production in HCT‐116 cells and distinct effects in MCF‐7 cells contribute to a deeper understanding of the cytotoxic mechanisms of compound 3e. Overall, these findings highlight the potential of the investigated compounds, particularly compound 3e, as effective inducers of apoptosis in cancer cells. Mechanistic insights into cell cycle arrest, caspase‐mediated apoptosis, and ROS modulation provide a comprehensive understanding of their cytotoxic effects. This study offers significant contribution to the development of promising anticancer agents and their therapeutic applications.

Dihydroartemisinin and zerumbone esters of ataluren and its analogs as anticancer agents and EGFR inhibitors

Synthesis and cytotoxic activity evaluation of novel dihydroartemisinin and zerumbone conjugates with 2-mercapto-1,3,4-oxadiazoles as potential EGFR inhibitors

Synthesis and Cytotoxic Activities of Novel Ether Conjugates of Dihydroartemisinin and Zerumbone: Evidenced by Intergrating Network Pharmacology and In Vitro Assay

Design and Synthesis of Novel Dehydroepiandrosterone Analogues As Potent Antiproliferative Agents

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

New Application of Novel Tetrazine Derivatives As Potent VEGFR-2 Kinase Inhibitors and Anti-Cancer Agents

Synthesis and Anti‐Proliferation Activity Evaluation of Novel 2‐chloroquinazoline As Potential EGFR‐TK Inhibitors

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Novel Dithiocarbamic Acid Esters Derived from 6-Aminomethyl-4-anilinoquinazolines and 6-Aminomethyl-4-anilino-3-cyanoquinolines As Potent EGFR Inhibitors.

Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties

Novel 1,2,3-Triazole-Coumarin Hybrid Glycosides and Their Tetrazolyl Analogues: Design, Anticancer Evaluation and Molecular Docking Targeting EGFR, VEGFR-2 and CDK-2

Study on the structure-activity relationship of dihydroartemisinin derivatives: Discovery, synthesis, and biological evaluation of dihydroartemisinin-bile acid conjugates as potential anticancer agents

Synthesis, Molecular Docking, and Anticancer Screening of Ester‐based Thiazole Derivatives

Structural optimization and biological evaluation for novel artemisinin derivatives against liver and ovarian cancers

Design, synthesis, biological evaluation, and molecular docking of novel quinazolinone EGFR inhibitors as targeted anticancer agents

Synthesis, biological evaluation, and molecular modeling studies of acetophenones‐tethered 1,2,4‐triazoles and their oximes as epidermal growth factor receptor inhibitors

Development and evaluation of novel artemisinin-isatin hybrids with potential anti-leukemic cytotoxicity

Design and synthesis of guaianolide‐germacranolide heterodimers as novel anticancer agents against hepatocellular carcinoma

Iodoquinazoline-derived VEGFR-2 and EGFRT790M dual inhibitors: Design, synthesis, molecular docking and anticancer evaluations

Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with/without thiourea skeleton as anticancer agents.

Synthesis of 3′-Methoxy-e-diethylstilbestrol and Its Analogs As Tumor Angiogenesis Inhibitors